Health Care [ 8/12 ] | Pharmaceuticals [ 50/74 ]
NASDAQ | Common Stock
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases.
The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.
Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration.
The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate.
BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 12, 26 | -0.52 Decreased by -44.44% | -0.63 Increased by +17.13% |
| Mar 19, 26 | -0.72 Increased by +28.00% | -0.67 Decreased by -7.69% |
| Nov 6, 25 | -0.56 Increased by +91.64% | -0.51 Decreased by -9.01% |
| Aug 6, 25 | -0.60 Increased by 0.00% | -0.38 Decreased by -57.32% |
| May 6, 25 | -0.36 Decreased by -140.00% | -0.53 Increased by +31.77% |
| Mar 20, 25 | -1.00 Decreased by -400.00% | -0.66 Decreased by -52.67% |
| Nov 7, 24 | -6.70 Decreased by -2.06 K% | -0.73 Decreased by -812.43% |
| Aug 28, 24 | -0.60 Decreased by -71.43% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 2.77 M Increased by +91.04% | -22.25 M Decreased by -72.13% | Decreased by -802.78% Increased by +9.90% |
| Dec 31, 25 | 3.08 M Increased by +N/A% | -25.94 M Decreased by -22.78% | Decreased by -842.85% Decreased by N/A% |
| Sep 30, 25 | 2.05 M Increased by +N/A% | -20.17 M Increased by +13.82% | Decreased by -982.04% Decreased by N/A% |
| Jun 30, 25 | 2.41 M Increased by +N/A% | -21.56 M Decreased by -58.77% | Decreased by -893.99% Decreased by N/A% |
| Mar 31, 25 | 1.45 M Increased by +N/A% | -12.93 M Increased by +0.49% | Decreased by -890.97% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by N/A% | -21.13 M Decreased by -0.82% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -23.41 M Decreased by -60.05% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -13.58 M Increased by +20.98% | Decreased by N/A% Decreased by N/A% |